"Triple positive" early breast cancer: an observational multicenter retrospective analysis of outcome. - Wikidata - awgldk - TriplyDB

"Triple positive" early breast cancer: an observational multicenter retrospective analysis of outcome.

"Triple positive" early breast cancer: an observational multicenter retrospective analysis of outcome.

http://www.wikidata.org/entity/Q37109643

about

Breast cancer subtype and stage are prognostic of time from breast cancer diagnosis to brain metastasis development.Current Therapies for Human Epidermal Growth Factor Receptor 2-Positive Metastatic Breast Cancer Patients.

P2860

Q48213140-AC493676-69F8-444B-BADF-C7FDF46BDE42 Q52578959-B6E1BAD7-74BA-4DE8-8F54-2688D6FE9663

P2860

"Triple positive" early breast cancer: an observational multicenter retrospective analysis of outcome.

http://www.wikidata.org/entity/Q37109643

description

article científic

@ca

article scientifique

@fr

articolo scientifico

@it

artigo científico

@pt

bilimsel makale

@tr

scientific article published on 18 February 2016

@en

vedecký článok

@sk

vetenskaplig artikel

@sv

videnskabelig artikel

@da

vědecký článek

@cs

name

"Triple positive" early breast ...... ospective analysis of outcome.

@en

"Triple positive" early breast ...... ospective analysis of outcome.

@nl

type

label

"Triple positive" early breast ...... ospective analysis of outcome.

@en

"Triple positive" early breast ...... ospective analysis of outcome.

@nl

prefLabel

"Triple positive" early breast ...... ospective analysis of outcome.

@en

"Triple positive" early breast ...... ospective analysis of outcome.

@nl

P1433

Q37109643-96B9AD83-CBB1-431A-89AA-57C5703B6512

P1476

Q37109643-9BE8FC55-350A-4151-97E7-7103E60C1E10

P2093

Q37109643-052FA191-3FE5-4479-A416-961C25A992BA

Q37109643-0B2757A0-769C-4953-8F65-2B7AD3F70FDF

Q37109643-0D7A06F2-6762-4634-BA5D-9743669AE5F3

Q37109643-1D03D6E3-A469-4100-83AE-279D56068FA5

Q37109643-1FE5B538-6ACC-480A-8DC7-605C24D7F7FD

Q37109643-295E2193-ABBF-4CCC-8CEA-E836725CE0B4

Q37109643-2BAC65B7-B1BA-43D7-8840-B126071B793A

Q37109643-33143DD7-3407-4FA8-B5D3-7B648184275F

Q37109643-38BED6BB-ECEA-4FE8-AFE4-38AB5FC58B3C

Q37109643-477564D8-56CC-4143-B3D3-7E8B28664A69

P2860

Q37109643-087B60E0-147B-4994-84FB-19379D944902

Q37109643-0A941D8A-1A74-40B1-A32F-0396471852E4

Q37109643-1413E8B0-C738-4A48-B80D-1B443C5903CA

Q37109643-15F27791-6AF2-41CA-8845-3D53834E168B

Q37109643-1773F31C-EB84-433D-90CB-0D8E50501100

Q37109643-1BD33BC6-5A8D-4D91-B3B7-7E15412F0AD6

Q37109643-297C44A8-0EDC-4209-84C8-BACC9341D1CD

Q37109643-2ADAF3B9-BC08-47F8-8E88-D43C8FA39957

Q37109643-30E1FC6D-4FEB-4952-9E0C-8D9F66E8F734

Q37109643-37D2E6F0-E891-4F28-BBDB-5C6A06823D2C

P304

Q37109643-93A03E03-DB06-4E61-804B-D5100B4E719B

P31

Q37109643-1F32FD7B-46B6-4046-8234-598FC4A49224

P356

Q37109643-C63D536F-6D97-4B54-AC4D-0E5A7B7DA05D

P407

Q37109643-5CB4060F-7AD2-496D-9BC4-AD08840F621C

P433

Q37109643-46EAFCA8-4B4B-4D28-B9FF-9534A79C5082

P478

Q37109643-D27F8F81-00EA-41B4-9DFC-6A1D072437D3

P50

Q37109643-11CFA251-5EF3-4A89-ABBF-55566E0E9404

Q37109643-32F652D2-9A2F-48D1-B3A7-9D407BDEF0D0

Q37109643-3E3BCB86-1D22-4055-9D5B-AA7AFC3FBED7

Q37109643-6A213D96-56AB-4568-9FBB-44F6770C1755

Q37109643-71600774-D8A8-4511-ADA8-AC9732C19C79

Q37109643-77E99312-0F5F-4B2F-B054-0E5345F3351C

Q37109643-839F741D-01B6-4597-A0A5-A06C5785B315

Q37109643-8AEADC7B-D836-4342-83B0-BDDA3348EE4F

Q37109643-A102ED35-9CE4-4CEA-93C2-3C212642F170

Q37109643-CC4574F5-B226-4912-9BB3-BF959EFCAAF5

P577

Q37109643-DAA45B55-7DD7-48B1-AAF0-E94F63CC7533

P698

Q37109643-6FADE29E-54A4-4037-9233-D2F64FBB135A

P921

Q37109643-414EBF7D-D5A3-442D-B86A-DA7619D35DD8

P932

Q37109643-5D7E3D1E-8609-403F-A574-AC66127B2C19

P356

ONCOTARGET.7480

P1433

P1476

"Triple positive" early breast ...... rospective analysis of outcome

@en

P2093

Alessandra Cassano

http://www.w3.org/2001/XMLSchema#string

Andrea Michelotti

http://www.w3.org/2001/XMLSchema#string

Angelo Fedele Scinto

http://www.w3.org/2001/XMLSchema#string

Daniele Santini

http://www.w3.org/2001/XMLSchema#string

Domenico Cristiano Corsi

http://www.w3.org/2001/XMLSchema#string

Editta Baldini

http://www.w3.org/2001/XMLSchema#string

Francesco Giotta

http://www.w3.org/2001/XMLSchema#string

Ilaria Bertolini

http://www.w3.org/2001/XMLSchema#string

Laura Pizzuti

http://www.w3.org/2001/XMLSchema#string

Loretta D'Onofrio

http://www.w3.org/2001/XMLSchema#string

P2860

Trastuzumab containing regimens for early breast cancer

Comprehensive molecular portraits of human breast tumours

Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): a randomised, open-label, multicentre, phase 3 trial.

Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene

Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): a randomised multicentre, open-label, phase 2 trial

A small sample study of the STEPP approach to assessing treatment-covariate interactions in survival data.

Breast Cancer Survival Defined by the ER/PR/HER2 Subtypes and a Surrogate Classification according to Tumor Grade and Immunohistochemical Biomarkers.

Outcomes of HER2-positive early breast cancer patients in the pre-trastuzumab and trastuzumab eras: a real-world multicenter observational analysis. The RETROHER study.

Genomic analysis reveals that immune function genes are strongly linked to clinical outcome in the North Central Cancer Treatment Group n9831 Adjuvant Trastuzumab Trial.

Intrinsic subtypes, PIK3CA mutation, and the degree of benefit from adjuvant trastuzumab in the NSABP B-31 trial.

P304

17932-17944

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.18632/ONCOTARGET.7480

http://www.w3.org/2001/XMLSchema#string

P407

P433

14

http://www.w3.org/2001/XMLSchema#string

P478

7

http://www.w3.org/2001/XMLSchema#string

P50

Maddalena Barba

Isabella Sperduti

Diana Giannarelli

Paolo Marchetti

Antonio Frassoldati

P577

2016-04-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

26910921

http://www.w3.org/2001/XMLSchema#string

P921

multicenter trial

P932

4951261

http://www.w3.org/2001/XMLSchema#string